Public Employees Retirement System of Ohio Sells 2,902 Shares of Cencora, Inc. $COR

Public Employees Retirement System of Ohio lessened its holdings in Cencora, Inc. (NYSE:COR) by 3.3% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 85,723 shares of the company’s stock after selling 2,902 shares during the period. Public Employees Retirement System of Ohio’s holdings in Cencora were worth $26,929,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of COR. T. Rowe Price Investment Management Inc. lifted its holdings in Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after acquiring an additional 4,123,795 shares during the period. Norges Bank purchased a new position in Cencora in the fourth quarter worth $822,506,000. Marshall Wace LLP grew its stake in Cencora by 518.9% in the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after purchasing an additional 1,672,762 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Cencora by 528.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after purchasing an additional 1,241,186 shares during the period. Finally, Viking Global Investors LP grew its stake in Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the period. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Evercore set a $360.00 target price on Cencora in a research note on Wednesday, April 8th. William Blair began coverage on shares of Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating for the company. Citigroup reduced their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Robert W. Baird decreased their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Barclays lowered their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 10th. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $367.75.

Insider Activity at Cencora

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the purchase, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This represents a 14.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.38% of the company’s stock.

Cencora Trading Up 1.5%

Shares of Cencora stock opened at $309.67 on Friday. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The stock’s 50-day simple moving average is $284.52 and its 200 day simple moving average is $316.47. The stock has a market capitalization of $60.25 billion, a P/E ratio of 23.75, a P/E/G ratio of 1.69 and a beta of 0.58. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s payout ratio is 18.40%.

Cencora announced that its board has initiated a stock repurchase program on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.